INCY Relative Valuation
INCY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, INCY is overvalued; if below, it's undervalued.
Historical Valuation
Incyte Corp (INCY) is now in the Undervalued zone, suggesting that its current forward PE ratio of 11.45 is considered Undervalued compared with the five-year average of 20.65. The fair price of Incyte Corp (INCY) is between 99.99 to 176.02 according to relative valuation methord. Compared to the current price of 69.08 USD , Incyte Corp is Undervalued By 30.92%.
Relative Value
Fair Zone
99.99-176.02
Current Price：69.08
30.92%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
3.66
P/B
Median3y
3.47
Median5y
4.53
2.26
FCF Yield
Median3y
3.24
Median5y
2.63
Competitors Valuation Multiple
The average P/S ratio for INCY's competitors is 7.09, providing a benchmark for relative valuation. Incyte Corp Corp (INCY) exhibits a P/S ratio of 2.79, which is -60.70% above the industry average. Given its robust revenue growth of 19.53%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Incyte Corp (INCY) currently overvalued or undervalued?
What is Incyte Corp (INCY) fair value?
How does INCY's valuation metrics compare to the industry average?
What is the current P/B ratio for Incyte Corp (INCY) as of Jul 18 2025?
What is the current FCF Yield for Incyte Corp (INCY) as of Jul 18 2025?
What is the current Forward P/E ratio for Incyte Corp (INCY) as of Jul 18 2025?